Formue

Lovende COVID-19 behandling sender aktier 3% op

Uddrag fra tidsskriftet STAT- læs hele artiklen

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

AChicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.

Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests.The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies.

If safe and effective, it could become the first approved treatment against the disease.The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.

[postviewcount]

Relaterede nyheder

Vestas’ svage ordreindgang må ikke overvurderes

Jobannoncer

Nyt job

CEO for Rejsekort & Rejseplan A/S

Region H

Nyt job

Controller/økonomimedarbejder – få den brede vifte af økonomiopgaver

Region H

Finance/Business Controller til Anzet A/S

Region Sjælland

Liftra ApS i Aalborg søger en Finance Controller med ”speciale” i Transfer Pricing

Region Nordjylland

Annonce

Hent udgivelser

Hent udgivelser

Gratis white papers:

Hent udgivelser

Gratis white papers:

Lovende COVID-19 behandling sender aktier 3% op

Morten W. Langer

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

Relaterede nyheder

Vestas’ svage ordreindgang må ikke overvurderes

Aktuelle aktier, der bør holdes øje med

Teknisk: DAX Future / Europæiske aktier viser tegn på ny styrke, men renter stiger stadig

Jobannoncer

Mere fra ØU Formue

Dybdegående og original
journalistik siden 1994

OM ØU

Sektioner

KONTAKT

Log ind

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Analyser med aktiestrategi, analytikerforventninger, finansblogs og råvarer

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Annonce

Hent udgivelser

Hent udgivelser

Gratis white papers:

Hent udgivelser

Gratis white papers:

Lovende COVID-19 behandling sender aktier 3% op

Morten W. Langer

Relaterede nyheder

Vestas’ svage ordreindgang må ikke overvurderes

Aktuelle aktier, der bør holdes øje med

Teknisk: DAX Future / Europæiske aktier viser tegn på ny styrke, men renter stiger stadig

Jobannoncer

Mere fra ØU Formue

Dybdegående og original journalistik siden 1994

OM ØU

Sektioner

KONTAKT

Log ind

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Analyser med aktiestrategi, analytikerforventninger, finansblogs og råvarer

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Dybdegående og original
journalistik siden 1994